Development of Insulin Detemir/Insulin Aspart Cross-Reacting Antibodies Following Treatment with Insulin Detemir: 104-week Study in Children and Adolescents with Type 1 Diabetes Aged 2 –16 Years

ConclusionAlthough treatment with IDet and IAsp is associated with development of specific and cross-reacting antibodies, no correlation between insulin antibodies and basal insulin dose or HbA1c was found.FundingNovo Nordisk A/S.ClinicalTrials.gov identifiers: NCT00435019 and NCT00623194.
Source: Diabetes Therapy - Category: Endocrinology Source Type: research